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Edited by Christian GriesingerAbstract We present here a new set of aminoglycoside-arginine
conjugates (AACs) that are either site-speciﬁc or per-arginine
conjugates of paromomycin, neamine, and neomycin B as well as
their structure–activity relationships. Their binding constants
(KD) for TAR and RRE RNAs, measured by ﬂuorescence
anisotropy, revealed dependence on the number and location of
arginines in the diﬀerent aminoglycoside conjugates. The binding
aﬃnity of the per-arginine aminoglycosides to TAR is higher
than to RRE, and hexa-arginine neomycin B is the most potent
binder (KD = 5 and 23 nM, respectively). The 2D TOCSY NMR
spectrum of the TAR monoarginine-neomycin complex reveals
binding at the bulge region of TAR.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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TAR-NeoR11. Introduction
The complexity and diversity of RNA structures oﬀer at-
tractive targets for small molecule ligands to be used as
pharmacological agents [1]. Aminoglycosides have found
clinical use as antibacterial agents, due to their ability to spe-
ciﬁcally bind bacterial ribosomes [2]. Aminoglycosides also
interact with a large number of other RNAs including the two
essential elements of the HIV genome, Rev responsive element
(RRE) and the transactivation responsive element (TAR) [3].
For example, the binding of neomycin B to HIV TAR in the
minor groove leads to conformational changes in TAR, thus
restricts HIV-1 transactivator protein, Tat, binding at the
major TAR-RNA groove [4,5]. The molecular basis of Rev-
RRE recognition requires interaction of the 17-mer arginine-
rich Rev (residue 33–50) peptide with a bulge portion of RRE
IIB RNA construct, which forms an A-form RNA duplex with
a 3 2 internal loop [6]. Non-canonical pairs GdA and GdG
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doi:10.1016/j.febslet.2004.10.038are essential for Rev recognition [7] (Fig. 1). The Tat–TAR
interaction involves an arginine-rich Tat peptide (residues 49–
57) and the three-nucleotide UCU bulge region of TAR,
ﬂanked by two double stranded stems (e.g., [8,9]) (Fig. 1).
Peptides carrying an arginine-rich sequence of Tat and even a
nona-arginine peptide bind TAR RNA at the UCU bulge with
high aﬃnity and speciﬁcity (e.g., [10,11]). Importantly, it was
reported that not only Tat peptide binds TAR RNA with high
aﬃnity, but the Rev peptide does as well, functionally substi-
tuting for Tat [11,12]. Thus, Rev peptide labeled with carb-
oxymethyl rhodamine (RhdRev; Fig. 1) was used in this study
as a ﬂuorescent probe for both TAR and RRE IIB RNA
constructs.
Arginine- and lysine-rich basic peptides comprise a common
motif of RNA recognition by proteins. For example, HIV-1
Tat and Rev proteins mediate their interactions with the viral
RNAs via arginine-rich motif [10]. Although the dominant
contributions of the arginine side-chains may diﬀer between
complexes, the ability of the guanidinium groups of the argi-
nine side chains to be involved in electrostatic interactions,
hydrogen bond formation and stacking interactions makes
arginine an important moiety for RNA recognition [13]. At-
tempts to mimic the arginine-rich peptides led to the devel-
opment of novel RNA ligands, which utilize a diverse set of
building blocks [14]. Arginine-rich RNA-binding peptides and
peptidomimetics have provided a good scaﬀold for RNA-tar-
geting drug design, since they are short, conformationally di-
verse and contact RNA with high aﬃnities and speciﬁcities.
We have recently shown that arginine-aminoglycoside con-
jugates (AACs) are far more eﬃcient anti-HIV-1 agents than
aminoglycosides, as these molecules comprise the RNA bind-
ing ability of aminoglycosides and the speciﬁc binding of ar-
ginine moiety to HIV-1 TAR RNA. AACs were designed to
bind HIV TAR RNA and to inhibit trans-activation by Tat
protein [14–16]. AACs are antagonists of the HIV-1 Tat pro-
tein basic domain and structurally are peptidomimetic com-
pounds with diﬀerent aminoglycoside cores and diﬀerent
numbers of arginines [16,17]. Along with inhibition of Tat
transactivation step in HIV life cycle, AACs exert a number of
other activities, closely related to Tat antagonism. For exam-
ple, hexa-arginine neomycin B conjugate (NeoR6) (Fig. 2)
inhibits the following functions of extracellular Tat protein:
upregulation of the HIV-1 viral entry via CXC chemokineation of European Biochemical Societies.
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Fig. 1. Structures of (A) TAR and (B) RRE IIB RNA oligonucleotides and (C) RhdRev Fluorescent probe.
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pression of CD3-induced proliferation of lymphocytes, and
upregulation of CD8 receptor [17]. We have shown thatO
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Fig. 2. Schematic representation of aminoglycoside-arginine conju-
gates and amino-glycosides used in this study. All AACs were prepared
as acetate salts. Hexa-arginine neomycin conjugate (NeoR6); a 1:1
mixture of two mono-arginine neomycin conjugates (NeoR1); a di-
arginine neomycin conjugate of neomycin B (NeoR2); a mono-arginine
neamine conjugate (NeamR1); a tetra-arginine neamine conjugate
(NeamR4); a mono-arginine paromomycin conjugate (ParomR1); and
a penta-arginine paromomycin conjugate (ParomR5).NeoR6 and tri-arginine gentamycin conjugate (R3G) inhibit
binding of HIV-1 particles to cells, probably by blocking the
CXCR4 co-receptor [17,18]. This was substantiated by the
ﬁnding that NeoR6 competes with the binding of the mono-
clonal antibody 12G5 to CXCR4; it also competes with the
binding of CXCR4-stromal cell derived factor 1a (SDF-1a) to
CXCR4 [17,19,20]. Moreover, NeoR6 crosses the blood brain
barrier when administered systemically and enters into various
brain tissues [21]. All of the above data suggest that AACs may
lead to an extremely important class of anti-HIV drugs. An
additional interesting property of AACs (e.g., NeoR6 and
R3G) is inhibition of bacterial (and to a lesser extent, mam-
malian) RNAse P activity 500 fold more eﬃciently than
neomycin B [22]. We have recently shown the capacity of
several AACs to inhibit peptidyl transferase activity [23].
The structure–function relationship of AACs with respect of
RNA binding is an important issue for drug development. We
hypothesized that similar to the recognition of 16S RNA by
rings I and II of neomycin B class of antibiotics, e.g., neamine
and paromomycin [24] (Fig. 2), being conjugated to arginine
would be suﬃcient to mediate speciﬁc interactions with the
HIV-1 RNAs. Thus, syntheses and characterization of site-
speciﬁc mono-arginine conjugates of neamine, paromomycin
and neomycin B, as well as tetra-arginine neamine, penta-ar-
ginine paromomycin, di- and hexa-arginine neomycin B con-
jugates (Fig. 2) were undertaken. Their binding to HIV-1 TAR
and RRE RNA, as presented by ﬂuorescence anisotropy,
points that hexa-arginine neomycin B (NeoR6) exerts the
highest binding aﬃnity to both RNAs. Although the mono-
arginine aminoglycoside conjugates bind TAR and RRE with
signiﬁcantly lower aﬃnity than the per-arginine conjugates, the
site of binding to TAR, as presented in this paper by 2D
1H NMR, reveals binding at the bulge region of TAR.2. Materials and methods
2.1. Materials
The procedure for the synthesis and puriﬁcation of NeoR6 [17], and
for NeoR1, NeoR2, NeamR1, NeamR4, ParomR1 and ParomR5 was
reported [25,26].
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A 31 residue TAR RNA fragment containing residues 19–44 HIV-1
LTR, the high aﬃnity Tat binding site, and a 41 residue RRE IIB
RNA fragment containing the high aﬃnity Rev binding site (Fig. 1)
were purchased from Dharmacon Research Inc (Boulder, CO); they
were deprotected using the company’s buﬀer and protocol. Rhoda-
mine-Rev peptide (residues 34–50 TRQARRNRRRRWRERQR)
(RhdRev) was prepared as previously described [27] and used as a
ﬂuorescence probe for binding to the 31-mer TAR RNA and to the 41-
mer RRE RNA. Tar and RRE RNA were annealed by heating to 95
C with gradual cooling to room temperature. All stock solutions were
prepared in nuclease-free water and were diluted with appropriate
buﬀers prior to use. RNA concentrations were determined spectro-
photometrically at 260 mm and the samples were re-annealed each
time.
Binding of RhdRev to HIV TAR RNA and AACs competition with
RhdRev on binding to TAR and RRE IIB RNAs were examined by
ﬂuorescence anisotropy [27,28], preformed on SLM-Aminco model
8100 Series 2 spectrometer (Spectronic Instruments) equipped with a
thermostat accurate to 0.1 C. The TAR binding samples (0–200 nM)
were excited at 550 nm and monitored at 580 nm; the integration time
was 4 s. Every point consists of 10–20 measurements and their average
values were used for calculation. Measurements were performed at 20
C in a buﬀer solution containing 85 mM NaC1, 2 mM KC1, 0.5 mM
MgC12, 0.5 mM CaC12 and 10 mM HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid] (pH 7.5) [27]. The RhdRev tracer con-
centration (0–70 nM) was determined spectroscopically at 550 nm
using a molar excitation coeﬃcient of 6.00 104 M1 cm1 [29]. Dif-
ferent AAC concentrations (0–500 nM in 20 nM increments) were used
for the competition studies.
2.3. Determination of binding constants
Eq. (1) was used for the calculation of the dissociation constants
(Kd) of the interaction of RNA and the ﬂuorescent tracer RhdRev
[29,28]
A ¼ A0 þ DAf½RNA0 þ ½tracer0 þ Kd  ½ð½RNA0 þ ½tracer0 þ KdÞ2
 4½RNA0½tracer01=2g=2; ð1Þ
where A and A0 are the ﬂuorescence anisotropy of RhdRev (tracer) in
the presence and absence of RNA, respectively, and DA is the diﬀer-
ence between the ﬂuorescence anisotropy of the tracer at extrapolation
to inﬁnite concentration of RNA minus the ﬂuorescence anisotropy in
the absence of RNA. [RNA]0 and [tracer]0 are the initial concentra-
tions of RNA and the ﬂuorescent tracer (RhdRev), respectively.
Eq. (2) [29] is used for the determination of KD values in the com-
petition-binding assay
½AAC0 ¼ ½KDðA1  AÞ=KdðA A0Þ þ 1½½RNA0  KdðA A0Þ
=ðA1  AÞ  ½tracer0ðA A0Þ=ðA1  AÞ; ð2Þ
where KD is the dissociation constant of RNA–AAC complex; [AAC]0
is the initial concentration of the aminoglycoside-arginine conjugates.
Both Kd and KD were determined by non-linear curve ﬁtting of the
experimental points using Kaleidagraph and Eqs. (1) or (2) describedB
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Fig. 3. Fluorescence anisotropy of the ﬂuorescently labeled Rev (RhdRev34
function of (B) RRE IIB RNA concentration.above and presented as mean values of three independent measure-
ments.
2.4. 2D-TOCSY NMR of TAR in the presence and absence of NeoR1
All NMR experiments were performed on Varian Inova 600 MHz
spectrometers using samples of 31-nucleotide TAR RNA at 0.8 mM, in
10 mM sodium phosphate buﬀer (pH 6.5), and 20 mM NaCl. Ho-
monuclear TOCSY spectra in D2O were recorded at 35 C. Spectra
were apodized via cosine-bell window functions in each dimension and
zero-ﬁlled once. The spectra were processed with NMRpipe [30] and
analyzed with SPARKY [31]. NOESY spectra were acquired from 10
to 35 C.3. Results and discussion
3.1. Rationale
Our recent studies [17] suggest that NeoR6 targets the Tat
transactivation step in the HIV-1 life cycle. NeoR6 displays
high in vitro inhibition of Tat–TAR interaction in a concen-
tration range of Tat-R52 peptide [16,17]. A model structure for
the TAR-NeoR6 complex, which complied with available
biochemical data, suggested possible binding of NeoR6 to
TAR RNA at the bulge region [17], the site for Tat basic
peptide binding [12,13]. To this end, the mode of binding of
diﬀerent aminoglycoside site-speciﬁc arginine conjugates and
the function(s) of the other arginine moieties on TAR or RRE
RNA binding were not yet investigated. Towards this goal, a
set of diﬀerent aminoglycosides conjugated to 1–6 arginines
was prepared, and their binding to TAR and RRE was mea-
sured as well as the binding of site speciﬁc mono-arginine
neomycin conjugate(NeoR1) to TAR was examined by
2D TOCSY 1H NMR.3.2. Binding of aminoglycoside-arginine conjugates to TAR and
RRE IIB RNA constructs
The initial experiment aimed at determining whether Rhd-
Rev peptide binding to TAR is similar or not to its interaction
with RRE IIB. TAR and RRE IIB constructs (Fig. 1) were
used in this study. The ﬂuorescence probe (10 nM) was titrated
with increasing concentrations of RRE IIB or TAR (0–60 nM)
in a buﬀer solution containing 85 mM NaCl. The ﬂuorescence
anisotropy changes were plotted as a function of increasing
concentration of RRE IIB or TAR. Non-linear curve ﬁtting
was used to determine the Kd of RhdRev-RNA complexes. The
isotherms for RhdRev binding to RRE IIB and TAR (Fig. 3AAn
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Table 1
Dissociation constants (Kd, KD, nM) of AACs binding to TAR and RRE RNA and IC50, determined by competitive experiments with RhdRevA
Compound KD TAR/RhdReva IC50 TAR/RhdRevb KD RRE IIBc IC50 RRE IIBd
RhdReve 7.3 0.5 – 16.6 2.7 –
NeoR6 5.0 0.2 19.9 2.7 23.3 0.9 72.7 10.1
NeoR2 >500f >500f 111.5 3.7 207.9 21.1
NeoR1 >500f >500f 200.2 5.9 352.8 31.9
ParomR5 15.1 0.4 34.3 5.7 95.9 2.2 149.4 12.3
ParomR1 >500f >500f 254.2 7.8 406.8 41.0
NeamR4 30.1 1.2 82.8 7.7 54.7 1.1 118.8 13.5
NeamR1 >500f >500f 233.4 4.5 342.4 29.5
aKD and bIC50 inhibitory concentration (IC50) determined by competition of AACs with RhdRev for TAR RNA binding; cKD and dIC50 determined
as competition of AACs with RhdRev for RRE IIB RNA binding; emeasured as direct binding of RhdRev to TAR and RRE IIB RNA; f20 lM of
mono and di-arginine aminoglycoside derivatives failed to completely expel RhdRev from the complex with TAR, thus IC500s and KD’s are >500 nM
and could not be accurately determined.
The Kd, KD and IC50 values are means of three independent measurements.
A The KD (lM) values 1.18 and 8.3 for neomycin B and paromomycin binding to RRE respectively; and IC50 (lM) values 28 and 21 for neamine
binding to TAR and RRE respectively were previously published [28,29,39].
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nM) and for RhdRev-TAR (7 nM) (Table 1) exhibit high
binding aﬃnity of RhdRev to TAR. This is in line with pre-
vious ﬁnding that Rev peptide binds TAR, functionally
substituting for Tat (10–12). Thus, RhdRev was used to de-
termine the KD of AACs-TAR and AACs-RRE complexes. In
these experiments to 10 nM of the ﬂuorescent tracer (RhdRev),
ﬁxed amount (20 nM) of TAR or RRE IIB RNA was added
(in a buﬀer containing 85 mM NaCl). The complexes of the
tracer and the corresponding RNA were further titrated with
various AACs and anisotropy values were recorded (Fig. 4A–
C). Using non-linear curve ﬁtting, the dissociation constants
ðKDÞ of AACs-TAR and AACs-RRE IIB RNA complexes
were determined (Table 1). The titration of RhdRev-RRE IIB
complex with AACs exhibited an expected decrease of an-
isotropy, indicating release of the ﬂuorescent tracer from the
complex, and resulted in accurate KD values for AACs-RNA
complexes. When similar competition experiments were per-
formed with RhdRev-TAR, only AACs with several arginine
side chains, such as NeoR6, ParomR5 and NeamR4, eﬃciently
compete with RhdRev for TAR binding (Table 1) (Fig. 4A–C).
The AACs, featuring one or two arginine side chains, failed to
completely expel the tracer from its complex with TAR and the
residual anisotropy did not return to its initial value; thus,
their KD values could not be accurately measured.
Noteworthy, the binding of NeoR6, ParomR5 and NeamR4
to TAR appeared to be more eﬃcient than to RRE IIB (Table
1). Overall, the measurements conﬁrmed that NeoR6 binds
with the highest aﬃnity to both RRE IIB (KD 23 nM) and
TAR (KD 5 nM) (Table 1), comparable to the natural ligands,
Rev residues 34–50 (40 nM) and Tat residues 49–57 (12 nM).
ParomR5 binds TAR with KD (15 nM), 3 times weaker than
NeoR6 and binds RRE IIB with KD (96 nM) about 4 times
weaker than NeoR6. NeamR4 binds TAR with KD (30 nM) 6
times weaker than NeoR6, while its binding to RRE IIB, KD
(55 nM) is only 2 times weaker than to NeoR6 (Table 1), i.e.,
NeamR4 binds RRE IIB more eﬃciently than ParomR5.
AACs with several arginines clearly bind TAR better than
RRE IIB. For comparison with published data (e.g., [32]), the
IC50 values for AACs competition with RhdRev for TAR and
RRE IIB were also determined (Table 1).
It is now well established that the dissociation constants of
aminoglycoside-RRE IIB RNA complexes are in the micro-
molar range. Even neomycin B that binds RRE IIB with thehighest aﬃnity (KD of 1.18 lM [29]) is about 550 times weaker
than hexa-arginyl neomycin B (NeoR6) and 6–7 times weaker
than mono- and di-arginine derivatives (NeoR1 and NeoR2).
This indicates that one arginine conjugated to neomycin B
already signiﬁcantly increases its binding aﬃnity to HIV-1
regulatory RNAs. Other aminoglycoside derivatives, e.g.,
guanylated aminoglycosides (e.g., [32]) or the tetra-c-guanid-
inobutyrate kanamycin A derivative (GB4K [15]), bind TAR
or RRE RNAs much weaker than AACs. Similarly, their anti-
HIV-1 activities are much lower than the respective arginine-
aminoglycoside derivatives [16–18]. This might be due to
diﬀerent binding sites on HIV RNAs for peptide and AAC
than other aminoglycoside derivatives. For example, we have
shown that GB4K binds to a diﬀerent region of TAR RNA
than Tat peptide (R52) or AACs [15,16]. Another example is
neomycin B, which binds RRE IIB in the major groove, at the
lower stem-bulge region of the construct, close to, but not at
the Rev peptide binding site (e.g., [33]). In the case of TAR
RNA, neomycin B binds in the minor groove in a region very
diﬀerent from the Tat binding site [4]. Both TAR and RRE
bind peptides in the major groove of the corresponding RNA
constructs. At least in the case of TAR RNA, tetra- to hexa-
arginylated AACs binding pattern is in accordance with the
peptide-like binding [10–12,19]. Based on our previous in vitro
binding studies to TAR RNA and anti-HIV-1 activities of
various arginine and guanidine derivatives of aminoglycosides,
we proposed that the a-amino groups of the arginine moieties
play an important role in TAR RNA site speciﬁc recognition
and in anti-HIV-1 activity [15,17]. Thus, AACs bear features
of both aminoglycosides and peptides.
We present here the structure-binding aﬃnity of AACs to
RNA, the KD values of AACs binding to TAR and RRE IIB
(Table 1) as a function of the number of arginine side chains
and the number of rings of the aminoglycoside core (Fig. 2).
NeoR6 displays the highest aﬃnity to TAR and RRE IIB (i.e.,
the lowest KD values), however, there is not much diﬀerence in
the aﬃnity of NeamR4 and ParamR5. NeamR4 renders even
lower KD value (higher aﬃnity) for RRE than ParomR5 does.
Thus, not only are the number of rings and arginine moieties
essential for eﬃcient RNA binding, but also the conjugation of
arginine to the methylamino group ðR1Þ of ring I aminogly-
coside is important to improve binding aﬃnity to RNA. While
neamine was suggested as a minimal RNA recognition unit
[24], arginine conjugated to rings I and II is not suﬃcient for
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Fig. 4. Fluorescence anisotropy of RhdRev (10 nM) solution containing [A] (a) TAR RNA (20 nM) and (b) RRE IIB RNA (20 nM), as a function of
various concentrations of NeoR6; [B] (a) TAR RNA (20 nM) and (b) RRE IIB RNA (20 nM), as a function of various concentrations of ParomR5;
[C] (a) TAR RNA (20 nM) and (b) RRE IIB RNA (20 nM), as a function of various concentrations of NeamR4.
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weaker RNA binder than NeoR6, suggesting that rings III and
IV and increased number of arginine moieties improve binding
aﬃnity of AACs to RRE and TAR RNAs.
Several structural studies of free and ligated RRE-IIB have
been published in the past few years (e.g., [33,34]). It was found
that the stem-loop RRE-IIB changes conformation upon
binding of Rev. Based on the available structures and the fact
that NeoR6 competes with Rev peptide (presented in this
study), assuming the same binding site or induced conforma-
tional changes in the RRE-IIB stem-loop region similar to
that of Rev, we anticipate that the interactions of arginine
moieties of NeoR6 are likely to imitate at least in part the
interactions of the arginine side chains of Rev with RRE. This
should be further investigated. Our experimental results sug-
gest that the arginine moieties at position R1 on ring I, and R3
and R4 on ring II (Fig. 2) are important for binding. The
important contribution of arginine at position R1 is demon-strated by the lower aﬃnity of ParomR5 to RRE IIB and TAR
compared to NeamR4. Thus, even though ParomR5 consists
of 4 rings and 5 arginine moieties it lacks arginine at position
R1 (Table 1 and Fig. 2), which is probably the reason for the
lower aﬃnity. The most potent binder, NeoR6, forms addi-
tional arginine-RRE interactions compared to NeamR4. These
observations are also in accord with the diﬀerences in arginine
side chain dynamics of Rev-RRE complex [34].3.3. TAR-NeoR1 complex binding site as determined by
1H NMR
While in vitro assays conﬁrm inhibitions, they do not ex-
plicitly show that the ligand binds to the designated site and
they do not preclude its binding to other sites. However, NMR
not only shows whether a ligand binds to the speciﬁc target but
also can reveal all sites on the target that interact with the li-
gand [35]. This requires resonance assignments for the target
Fig. 5. Chemical shift changes of TAR RNA upon NeoR1 binding. 1H
NMR TOCSY spectra of TAR RNA (0.8 mM) in the absence (red)
and presence of either 0.3 mM (yellow) or 0.9 mM NeoR1 (blue). The
spectra were acquired at 35 C.
420 A. Lapidot et al. / FEBS Letters 577 (2004) 415–421TAR RNA, which are available to us [35,36]. NeoR1 was se-
lected as a simpler form for the NMR study. As anticipated,
the NMR data demonstrate binding to the 50 bulge of TAR,
i.e., to the site of Tat protein binding. The 50 bulge contains
three pyrimidine residues (U23, C24 and U25) that can be
monitored by their H5–H6 cross-peaks in 2D TOCSY spectra
(Fig. 5). These can be compared with the H5–H6 cross-peaks
due to other pyrimidine residues. The overlaid TOCSY spectra
with increasing amounts of NeoR1 added to TAR show the
largest chemical shift changes for U23 and C24, with smaller
changes for residues up to three base-pairs away from the
bulge. None of the signals from loop residues were altered
upon binding NeoR1. Experiments with aminoglycoside con-
jugates containing multiple arginines also showed selective
perturbations in the pyrimidine resonances of bulge residues;
however, the spectra for NeoR1 are shown, since the NeoR1
complex was used for further NOE experiments, because all
resonances of the ligand are readily assigned. Unfortunately,
the NeoR1 complex exhibits a lack of intermolecular NOE
cross-peaks in any NOESY spectrum acquired from 10 to
35 C (not shown). The NOE spectra revealed shifts in RNA
peaks but no useful additional information is obtained, since
the shifts occurred in the bulge region. The TOCSY spectra of
TAR–NeoR1 complex are in line with our published foot-
printing analysis of the TAR-AACs (R3G and R4K) and
TAR–Tat R52 complexes [16]. While binding to the bulge was
also seen with promazines as ligands [37], the pattern of shifts
is signiﬁcantly diﬀerent [37] suggesting that NeoR1 binds in a
diﬀerent fashion than promazines to TAR although it binds in
the same vicinity.4. Conclusions
The development of a new class of HIV-1 inhibitors, tar-
geting viral components other than HIV reverse transcriptase
or protease, is of special importance in view of the failure, inmany cases, of the current antiretroviral therapies, and due to
the emergence of highly variable resistant HIV-1 strains. A
current direction in this ﬁeld is the development of HIV Tat
and Rev inhibitors, which may be critical for anti-AIDS
strategies.
We present here a new set of AACs, which are either
site-speciﬁc or per-arginine conjugates of aminoglycosides:
neomycin B, paromomycin and neamine, and their binding
aﬃnities to TAR and RRE IIB. The hexa-arginine neomycin B
conjugate reveals the highest binding aﬃnity either to TAR or
RRE IIB. AACs with several arginine groups bind TAR better
than RRE IIB. Despite the low eﬃcient binding of mono-
substituted AACs, the 2D TOCSY NMR spectra of the TAR-
NeoR1 complex reveal binding at the bulge region of TAR.
The role of a site-speciﬁc arginine and the function(s) of the
other arginine moieties of per-arginine conjugates of diﬀerent
aminoglycosides are being investigated. The new AACs exert a
number of activities related to Tat antagonism [18,38]. AACs
not only target two essential structural elements of the HIV
genome but also represent a novel family of inhibitors of viral
entry into human cells. It is worth mentioning that the new
AACs are not toxic to a large variety of human cell cultures
measured up to 500 lM [18], nor to mice (e.g., NeoR6) given
two single intravenous doses of 25 mg/kg of body weight over
the course of 2 h.Acknowledgements: This work was supported by internal grants of the
Weizmann Institute of Science to Aviva Lapidot and by NIH grant
AI46967 to T.L. James.References
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